RxDoctor Payments Data

Charles Patorgis, OD

Optometrist · Atlanta, GANPI 1063476729

Payments from drug & device makers

$548in general payments, 2019–2025

Across 16 payments — averaging $34.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$198
  • Harrow Eye, LLC$101
  • Ivantis, Inc$99
  • Novartis$36
  • Tarsus Pharmaceuticals, Inc.$28
  • Sun Pharmaceutical Industries Inc.$24
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$548100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$548 in reported general payments places this provider in the 40th percentile of 1,285 optometrist providers in Georgia.

See all optometrist providers in Georgia

Medicare billing

Part B allowed, 2024
$109,390
Medicare patients
681
Services billed
1,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost61$25,476
XiidraLifitegrast26$23,017
RestasisCyclosporine35$17,687
Latanoprost579$5,212
Brimonidine Tartrate108$4,357
Travoprost28$3,927
CombiganBrimonidine Tartrate/Timolol11$2,745
Timolol Maleate279$2,684
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$2,439
Brinzolamide14$1,916
Dorzolamide Hcl83$1,440
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat54$1,412
Tobramycin-DexamethasoneTobramycin/Dexamethasone32$1,130
Prednisolone Acetate25$636
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha65$573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$198$45,909107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,285 optometrist providers in Georgia.

Other optometrist in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →